Adimab congratulates GSK on additional approvals for depemokimab across the EU and China, following prior approvals in the US, Japan, and the UK. The first ultra-long-acting biologic of its kind, depemokimab was engineered using Adimab's proprietary yeast-based platform.

Adimab announces continued clinical momentum in 2025, with 11 new partner programs entering the clinic. To date, 89 Adimab-enabled programs have advanced to the clinic, with six partner programs now on the market.

Adimab entered into 23 new partnerships, added 75 new programs, and achieved 50 milestones in 2025. To date, the company has generated more than 650 therapeutic programs.

Five therapeutic products containing molecules discovered or optimized by Adimab have been approved for commercial sale.

Adimab has entered into partnership agreements with 17 new companies in 2024, expanded eight of its current partnerships, and achieved 51 technical and development milestones across numerous collaborations.